NASDAQ:TELA - Nasdaq - US8723811084 - Common Stock - Currency: USD
TELA BIO INC
NASDAQ:TELA (2/11/2025, 4:30:01 PM)
After market: 2.6 -0.01 (-0.38%)2.61
-0.06 (-2.25%)
The current stock price of TELA is 2.61 USD. In the past month the price decreased by -6.12%. In the past year, price decreased by -64.15%.
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (
MALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 29.74 | 44.88B | ||
COO | COOPER COS INC/THE | 25.26 | 18.65B | ||
ALGN | ALIGN TECHNOLOGY INC | 22.54 | 15.72B | ||
SOLV | SOLVENTUM CORP | 17.7 | 12.72B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 32.3 | 6.33B | ||
LNTH | LANTHEUS HOLDINGS INC | 11.8 | 5.70B | ||
BLCO | BAUSCH + LOMB CORP | 26.39 | 5.67B | ||
ICUI | ICU MEDICAL INC | 27.78 | 3.86B | ||
XRAY | DENTSPLY SIRONA INC | 9.88 | 3.63B | ||
HAE | HAEMONETICS CORP/MASS | 14.55 | 3.09B | ||
NEOG | NEOGEN CORP | 25.4 | 2.20B | ||
UFPT | UFP TECHNOLOGIES INC | 37.37 | 2.01B |
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 227 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
TELA BIO INC
1 Great Valley Parkway, Suite 24
Malvern PENNSYLVANIA 19355 US
CEO: Antony Koblish
Employees: 227
Company Website: http://www.telabio.com/
Investor Relations: http://ir.telabio.com
Phone: 14843202930
The current stock price of TELA is 2.61 USD.
The exchange symbol of TELA BIO INC is TELA and it is listed on the Nasdaq exchange.
TELA stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for TELA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of TELA.
TELA does not pay a dividend.
TELA does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.69).
The outstanding short interest for TELA is 1.06% of its float.
ChartMill assigns a fundamental rating of 3 / 10 to TELA. TELA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months TELA reported a non-GAAP Earnings per Share(EPS) of -1.69. The EPS decreased by 17.96% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -78.32% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 84% to TELA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 33.46% and a revenue growth 29.1% for TELA